At CIIC, we have developed a world-class solution to supply key radioisotopes, producing two products that are ideally suited to electron linear accelerator production:
Cu-67, a therapeutic isotope in emerging drugs used for cancer treatments, and
Mo-99/Tc-99m required by nuclear medicine physicians for early stage diagnosis of disease (such as cancer & cardiovascular disease).
We use an advanced method of producing and distributing key medical isotopes. Our method is the first commercially viable alternative to conventional reactor-based production.